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Abstract BACKGROUND: Hypertension during pregnancy is a heterogeneous group of 
disorders with elevated blood pressure with or without proteinuria. The multiple 
researches are held on the subject of a genetic conditioning of preeclampsia and 
pregnancy induced hypertension. 
OBJECTIVES: The study was designed to evaluate the impact of the single nucleo-
tide polymorphism (SNP) rs7579169 on hypertension disorders in pregnancy, 
especially on PE and PIH as well as on the perinatal outcome.
METHODS: It is a case–control study. The study included 104 women with 
uncomplicated pregnancies in the control group and 75 pregnant women with 
hypertension disorders in the study group, hospitalized in the Perinatology and 
Obstetrics Department of the University Hospital in Cracow. Genomic DNA was 
extracted from peripheral blood leukocytes and SNP rs7579169 was genotyped 
from all patients. We analyzed the genotypes distribution and allele frequencies of 
polymorphism rs7579169 and its association with perinatal outcome in all groups. 
A p-value <0.05 was considered as significant.
RESULTS: Clinical evaluation included standard anthropometric measures like 
weight and height for the calculation of the body mass index in the beginning 
and in the end of the pregnancy, blood pressure, time and a method of delivery, 
birth weight, Apgar score. The heterozygote CT was associated with a 4.5-fold 
increased risk of preeclampsia in pregnant patients. The presence of TT genotype 
significantly increased the risk of intrauterine growth restriction (<10 percentile). 
CONCLUSIONS: The study show probable impact of SNP rs7579169 on pregnancy, 
but further studies on larger groups are needed.
Abbreviations:
BMI  - body mass index
CG  - control group 
CH  - chronic hypertension 
eNOS  - endothelial nitric oxide synthase 
GWAS  - genome-wide association 
GWLS  - Genome-wide linkage screens 
INHBB  - inhibin beta B 
MAP  - mean arterial pressure
NHBPEP-WG  - the National High Blood Pressure Education
  Program Working Group
PE  - preeclampsia 
PIH  - pregnancy induced hypertension 
SNP  - single nucleotide polymorphism 
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INTRODUCTION
Hypertension during pregnancy is a heterogeneous 
group of disorders with elevated blood pressure with or 
without proteinuria. It is one of the most common preg-
nancy complication, responsible for high mortality and 
morbidity both of a mother and a child (Langenveld 
et al 2011; Aali et al 2004). In 10% to 15% preeclamp-
sia and eclampsia are responsible for direct maternal 
deaths of pregnant women (Duley 2009). There is no 
other effective treatment than finishing the pregnancy, 
as the expectant management of severe preeclampsia 
before 25 weeks of gestation is complicated with nearly 
95% intrauterine fetal loss rate (Sezik et al. 2007). All 
over the world multiple researches are held among 
others on the subject of genetic conditioning of pre-
eclampsia and pregnancy induced hypertension. 
Although many information has been gathered, still the 
fully understanding of etiology is unknown. The usage 
of the identified risk factors of the disease is limited 
and in the stage of the clinic study, what is connected 
with the complexity of the disease itself. Many variables, 
like environment, diet, style of life, socioeconomical 
conditions and stress have an impact on the genetic 
expression and the progress of the disease. The model 
of genetic heredity of preeclampsia, pregnancy induced 
hypertension or essential hypertension is not ready yet, 
despite many years’ studies (Williams & Morgan 2012). 
Genetic polymorphism is an existence of two or 
more different alleles in one locus in DNA, more often 
than it is expected, according to mutation frequency in 
a population. Both the mutation and polymorphism is 
a qualitative and/or quantitative change in the genetic 
material. Single nucleotide polymorphism (SNP) is a 
point mutation, like insertion, deletion or substitution 
of one of the nucleotides in coding or uncoding DNA 
sequence. A wide range of methods of finding polymor-
phisms is now available, like a genome-wide association 
scan (GWAS) or Genome-wide linkage screens (GWLS). 
One study reported the results of the GWAS in which, as 
the first, a risk locus for preeclampsia on chromosome 
2q14, near the inhibin beta B (INHBB) gene was iden-
tified. In that study researchers had successfully geno-
typed 648,175 SNPs in 538 preeclampsia cases and 540 
normal pregnancy controls with the usage of the Illu-
mina OmniExpress-12 BeadChip (Johnson et al. 2012).
The aim of the present study was evaluation of the 
impact of the novel SNP rs7579169 located on chro-
mosome 2q14.2, on the preeclampsia and pregnancy 
induced hypertension as well as on the perinatal 
outcome.
MATERIAL AND METHODS
179 pregnant patients were randomly enrolled in the 
study from the women hospitalized in the Obstetrics 
and Perinatology Department of the University Hospi-
tal in Cracow. It is a case-controlled study. Hypertension 
and proteinuria were defined according to NHBPEP-
WG (2000). The hypertensive patients were divided 
into smaller groups depending on the final diagnosis 
of preeclampsia (PE), pregnancy induced hypertension 
(PIH) or chronic hypertension (CH) in number of 29, 
35 and 11 patients respectively. The hypertension was 
considered if the systolic/diastolic blood pressure was 
≥140/90 mmHg in two separated measurements. If the 
proteinuria occurred with hypertension after end of 20th 
week of pregnancy we diagnosed the preeclampsia. The 
exclusion criteria included: multiple pregnancy, still-
birth, fetal anomalies, patients with renal, liver or heart 
diseases as well as the withdrawal of patient’s consent. 
104 normotensive pregnant women were enrolled as a 
control group (CG) aged 18 to 39 years. Written informed 
consent was obtained from all the patients enrolled in 
this study and this study was approved by local Ethic 
Committee of Jagiellonian University. Each patient was 
interviewed and detailed medical history like gravidity, 
parity, week of gestation was taken. Clinical evaluation 
included standard anthropometric measures like body 
weight and height for the calculation of the BMI in the 
beginning and in the end of pregnancy, blood pres-
sure (systolic, diastolic and MAP), time and a method 
of the delivery, the fetal birth weight, the Apgar score.
Samples of venous blood from all the patients were 
collected into EDTA tubes while standard medical 
procedures during hospitalization. The blood samples 
were kept at –80 °C for some time as all of the samples 
were analyzed at the same time. Genomic DNA was 
extracted from peripheral blood leukocytes using the 
standardized protocols (NHBPEP-WG 2000). The 
DNA extraction was performed with High Pure PCR 
Template Preparation Kit. The DNA quality and quan-
tity was assessed on a spectrophotometer NanoDrop 
ND-1000. DNA was amplified by PCR with prim-
ers designed in the Primer 3 Input program (v. 0.4.0): 
P-F1: 5’-CTGCTCTATGGCTTCCCAAG-3’ P-R1: 
5’-TGAGCGAACTCAGGCACA-3’. Genotyping was 
performed by investigators blinded to clinical status.
The characteristics of the study groups were com-
pared properly by Kruskal-Wallis test, Mann-Whitney 
test, Fisher’s exact test, chi-square test, Classical analysis 
of variance and post-hoc Tuckey test. The distribution 
of the genotype variants among studied subjects were 
compared by chi-squared analysis and test Fisher’s 
exact. Odds ratios were calculated as a measure of the 
association between the genotypes and clinical pheno-
types. For each odds ratio, P values and 95% confidence 
intervals were calculated. A P value of <0.05 was con-
sidered as statistically significant. The results were ana-
lyzed with IBM SPSS Statistics v.20.
RESULTS 
The clinical characteristics of the studied popula-
tion are presented in Table 1. Pregnant women with 
hypertension and normotensive pregnant patients were 
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homogeneous for gestational history and height, but 
significant differences were found in the age, blood 
pressure (systolic, diastolic and mean p<0.001) and 
weight measurements before and during pregnancy. 
The gestational age at the birth and birth weight were 
significantly lower in preeclampsia and chronic hyper-
tension (Table 2).
The rs7579169 polymorphism was in Hardy-Wein-
berg equilibrium. We analyzed the genotypes distribu-
tion and allele frequencies of polymorphism rs7579169 
in all groups (the data summarized in Table 3). There 
were no significant differences in genotype frequencies 
between the hypertensive groups and the control panel 
when analyzing data under a codominant (TT, TC, CC) 
Tab. 1. Summary of patient characteristics.
CH (n=11) PIH (n=35) PE (n=29) CG (n=104) p-value
Primigravid, n, % 4, 36.4% 16, 45.7% 16, 55.2% 48, 46.2% pchi=0.7
Nulliparous, n, % 6, 54.5% 20, 57.1% 19, 65.5% 56, 53.8% pF=0.7
Pregnancy loss, n, % 3, 27.3% 7, 20.0% 6, 20.7% 15, 14.4% pF=0.5
Height, cm
mean±SD
min – max
n=10
165.3±6.6
155–174
n=34
165.9±6.1
150–176
n=27
163.1±6.2
150–175
n=85
165.8±6.5
150–186
pA=0.3
Maternal age, years 
mean±SD
min – max
34.9±3.8
28–39
30.6±6.2
21–44
30.5±4.3
25–39
29.1±4.4
18–39
pMW=0.004
(1)
Body weight before pregnancy, kg
mean± SD
min – max
n=10
83.1±23.0
54–117
n=31
69.2±12.3
48–104
n=25
61.1±13.8
45–93
n=77
62.7±9.8
42–86
pKW=0.001
(2)
BMI before pregnancy, kg/m2
mean±SD
min – max
n=10
30.3±7.8
21.6–41.5
n=31
25.3±5.1
17.9–41.7
n=25
22.8±4.2
17.2–32.2
n=77
22.8±3.4
16.8–31.6
pKW=0.002
(3)
Weight gain during pregnancy, kg
mean±SD
min – max
n=10
9.7±9.2
–15do18
n=31
15.2±6.2
6–30
n=25
16.0±7.1
6–36
n=78
14.9±5.1
[5–32]
pKW=0.2
A – Classical analysis of variance; BMI – Body mass index; CG – control group; CH – chronic hypertension; chi – chi-square test, df=3; 
F – Fisher’s exact test; KW – Kruskal-Wallis test; MW – Mann-Whitney test; PE – preeclampsia; PIH – pregnancy induced hypertension; 
SD –standard deviation
(1) post-hoc Tuckey test: chronic hypertension group vs. gestational hypertension p=0.045; chronic hypertension vs. preeclampsia p=0.044; 
chronic hypertension vs. the control group, p= 0.001; other pairwise comparisons p>0.05
(2) post-hoc Tuckey test chronic hypertension group vs. gestational hypertension p=0.012; chronic hypertension vs. preeclampsia P<0.001; 
chronic hypertension vs. control group, p<0.001, other pairwise comparisons p>0.05
(3) post-hoc Tuckey test chronic hypertension vs. gestational hypertension p=0.011; chronic hypertension vs preeclampsia p<0.001; chronic 
hypertension vs. control group p<0.001; gestational hypertension vs. control group p=0.028; other pairwise comparisons p>0.05
Tab. 2. Perinatal outcomes.
CH PIH PE CG p-value
Gestational age at delivery, weeks
mean±SD
min - max
n=11
35.0±5.1
26–41
n=35
38.1±27
28–41
n=29
35.1±3.9
26–40
n=104
39.6±1.3
36–42
pKW<0.001
(1)
Infant birth weight, g 
mean±SD
min – max
n=11
2213±999
920–3710
n=35
3067±840
720–4130
n=29
2227±955
590–4400
n=104
3485±413
2500–4430
pKW<0.001
(2)
Intrauterine growth restriction, n, %
Eutrophic child 6, 54.5% 27, 77.1% 13, 44.8% 91, 88.3% pF<0.001
Hypotrophic child 5, 45.5% 8, 22.9% 16, 55.2% 12, 11.7%
CG – control group; CH – chronic hypertension; F – Fisher’s exact test; KW – Kruskal-Wallis test; PE – preeclampsia; PIH – pregnancy induced 
hypertension; SD – standard deviation
(1) post-hoc Tuckey test: chronic hypertension group vs. gestational hypertension, p=0.003; chronic hypertension vs controls, p<0.001; 
gestational hypertension vs. preeclampsia, p<0.001; gestational hypertension vs controls, p=0.012; preeclampsia vs control, p<0.001 , the 
remaining pairwise comparisons p>0.05
(2) post-hoc Tuckey test: chronic hypertension group vs. gestational hypertension p=0.002; chronic hypertension vs controls, p<0.001; 
gestational hypertension vs. preeclampsia p<0.001 vs control preeclampsia p<0.001, other pairwise comparisons p>0.05
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and dominant (CT+CC versus TT) model. However, in 
the recessive model (CC frequency versus TT+CT fre-
quency) the difference between the groups was found 
statistically significant (p=0.018). Moreover, the allele 
C was most common in patients with chronic hyperten-
sion (86.4%) (Table 3).
Different clinical parameters like weight changes 
during pregnancy were then compared among the 
three groups defined by the polymorphism genotypes. 
The results of this comparison, given in Table 4, show 
a significant relationship between the presence of TT 
genotype and the weight gain and BMI changes during 
pregnancy. Also interestingly the presence of TT geno-
type showed significantly increased risk of IUGR <10 
percentile (OR=4.30, 95% CI=1.2–15.1, p=0.023) in the 
multidimensional model standardized for maternal age, 
the incidence of miscarriages in the past, mothers’ BMI 
in early pregnancy (Table 5). It was shown in Table 6 
that the heterozygote CT was associated with a 4.5-fold 
increased risk of preeclampsia in the multidimensional 
model (OR=4.59; 95% CI 1.31–16.1, p=0.01).
No association was found between this polymor-
phism and the blood pressure (mean, systolic or dia-
stolic), the Apgar score and other analyzed data (data 
not shown).
DISCUSSION
Hypertensive disease during pregnancy is a crucial peri-
natal problem. It has been noticed that preeclampsia 
occurs more often among people who are related, which 
was the cause of significant suspicion of hereditary pre-
disposition (Cnattingius et al. 2004). Preeclampsia has a 
familial association as it was shown that daughters of PE 
affected women were having more than twice the risk of 
developing preeclampsia. What is more, the maternal 
association is stronger than the fetal association. The 
familial association predicts more severe pre-eclampsia 
Tab. 3. Distribution of the polymorphism rs7579169 genotype and alleles between study groups and normal pregnancy women.
CH PIH PE CS p-value
Codominant, n, %
CC 8, 72.7% 11, 31.4% 6, 20.7% 42, 40.4% pF=0.1
CT 3, 27.3% 18, 51.4% 17, 58.6% 49, 47.1%
TT 0, 0.0% 6, 17.1% 6, 20.7% 13, 12.5%
Recessive, n,%
CC 8, 72.7% 11, 31.4% 6, 20.7% 42, 40.4% pF=0.02
TT+CT 3, 27.3% 24, 68.6% 23, 79.3% 62, 59.6%
Dominant, n, %
CT+CC 11, 100.0% 29, 82.9% 23, 79.3% 91, 87.5% pF=0.4
TT 0, 0.0% 6, 17.1% 6, 20.7% 13, 12.5%
Alleles, n, %
C 19, 86.4% 40, 57.1% 29, 50.0% 133, 63.9% df=3
pchi=0.02T 3, 13.6% 30, 42.9% 29, 50.0% 75, 36.1%
CG – control group; CH – chronic hypertension; chi – chi-square test; F – Fisher’s exact test; PE – preeclampsia; 
PIH – pregnancy induced hypertension; 
Tab. 4. Weight changes during pregnancy depending on the polymorphism rs7579169 genotype.
CC (n=56) CT (n=68) TT (n=19) p-value
Weight gain during pregnancy, kg mean±SD
min – max 14.5±6.5
–15do30
14.2±5.3
6–30
17.9±7.5
9–36
PA=0.06
Weight gain during pregnancy, % mean±SD
min – max 23.1±10.9
–15–54.8
22.7±9.7
6.7–50.0
30.2±12.2
14.3–57.1
PA=0.02
(1)
BMI change during pregnancy, kg/m2 mean±SD
min – max 5.3±2.3
–5.4–9.9
5.2±1.8
2.1–10.8
6.6±2.9
2.8–14.1
PA=0.04
(2)
A – Classical analysis of variance; BMI – Body mass index; SD – standard deviation;
(1) post-hoc Tuckey test, group CC vs TT p=0.032; CT vs TT p=0.019;
(2) post-hoc Tuckey test, group CT vs TT p=0.038;
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(Skjaerven et al. 2005). Among many “genes candidates”, 
which may have an impact on the origin of hyperten-
sion disease during pregnancy, include those which 
products regulate the blood pressure, water-sodium 
homeostasis and cardiovascular system, like renin-
angiotensin-aldosteron system. Currently it is believed, 
that it is a multigenetic disease with great role of the 
epigenetic. The pathogenesis of preeclampsia includes 
abnormalities in the endothelial nitric oxide synthase 
(eNOS) and the nitric oxide pathway. The Two studies, 
which have had investigated serum levels of inhibin B 
in pregnancy, have reported lower (Petraglia et al. 1997) 
or no difference (Yair et al. 2001) in maternal serum 
in preeclamptic women as compared to normotensive 
pregnancies. Inhibin beta B is a subunit of the inhibin 
B. The novel polymorphism rs7579169 is located 
on chromosome 2q14.2, close to the Inhibin beta B 
(INHBB) gene. Its role is still unknown. Polymorphism 
rs7579169 was first found in performed genome-wide 
association study (GWAS) for preeclampsia in unre-
lated Australian individuals of the Caucasian ancestry 
(Johnson et al. 2012). The researchers were not able to 
replicate the associations in cohorts from Norway and 
Finland, concluding that it is more likely for the SNP to 
be in linkage disequilibrium with unidentified causal 
variant(s). The authors found no literature about the 
clinical significance or possible pathomechanism of 
analyzed SNP. Nevertheless, on the base of the present 
study some conclusions can be made, especially about 
mother gain weight and perinatal outcomes. 
The polymorphism rs7579169 may play a role in 
different aspects of pregnancy like the change of the 
weight gain of the pregnant woman on the one side, as 
well as on the growth of the fetus and birth weight of 
the child on the other. The presence of genotype TT 
was associated with bigger mother weight gain during 
pregnancy and increased risk of fetal hypotrophy. The 
significant differences between the genotypes distribu-
tion and allele frequencies of polymorphism rs7579169 
in the analyzed groups show the probable influence of 
the studied SNP on the risk of the hypertension during 
pregnancy. The probable impact is shown especially on 
the preeclampsia, while heterozygote CT of the SNP 
rs7579169 was associated with even a 4.5-fold increased 
risk of the disease taking into account some confound-
ing variables. While these results do not directly sup-
port any possible pathomechanism between the novel 
SNP and preeclapmsia, this study may contribute to 
better understanding of the subtle interactions between 
the polymorphic genetic structure and the pregnancy 
complication risks. More studies on larger groups are 
needed.
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